References: Castleman disease detailed guide
Bowne WB, Lewis JJ, Fillipa DA, et al. The management of unicentric and multicentric Castleman disease. Cancer. 1999;85:706–717.
Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001;92:670–676.
Dispenzieri A, Gertz MA. Treatment of Castleman's disease. Curr Treat Options Oncol. 2005;6:255–266.
Galeotti C, Tran TA, Franchi-Abella S, et al. IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease: Case report. J Pediatr Hematol Oncol. 2008;30:920–924.
Greiner TC, Gross TG. Atypical immune lymphoproliferations. In: Hematology: Basic Principles and Practice, 5th ed. Hoffman R, Benz Jr. E, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop H, eds. Philadelphia, PA. Elsevier; 2009: 1449–1459.
Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998;128: 657–662.
McClain KL, Natkunam Y, Swerdlow SH. Atypical cellular disorders. Hematology 2004. American Society of Hematology; 2004: 291–296. Accessed at: http://asheducationbook.hematologylibrary.org/content/2004/1/283.full on April 3, 2012.
Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627–2632.
Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood. 2003;102:2786–2788.
Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A. Multicentric Castleman's disease in HIV infection: A systematic review of the literature. AIDS Rev. 2008;10:25–35.
Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol. 2009;20:775–779.
Talat N, Schulte KM. Castleman's disease: Systematic analysis of 416 patients from the literature. Oncologist. 2011;16:1316–1324.
van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010;28:3701-3708.
Last Medical Review: 06/11/2012
Last Revised: 06/11/2012